Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes

Figure 3

Long-term tracking of eGFR-related data; eGFR: estimated glomerular filtration rate (mL/min/1.73 m²); DPG: dapagliflozin; EPG: empagliflozin. (a) Proportion of patients with different renal function stages at 0 and 36 months. Range of eGFR values by bars: CKD stage 1: ≥ 90; CKD stage 2: 60~89; CKD stage 3a: 45~59; CKD stage 3b: 30~44 (mL/min/1.73 m²). (b) Box plots indicate the eGFR values compared to baseline levels after 6, 12, 18, 24, 30, and 36 months of treatment. (c) Change in clinical parameters from baseline values to 36 months for long-term users.

(a)

(b)

(c)